secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-023727
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma Q2 2025 net loss narrows to $2.1M; cash at $4.8M; CDI-988 Phase 1 data positive
--------------------------------------------------------------------------------

- Q2 2025 net loss of $2.1M ($0.20/share) vs $5.3M ($0.53/share) in Q2 2024, primarily on lower R&D costs.
- Cash and equivalents $4.8M as of June 30, 2025, down from $9.9M at Dec 31, 2024; working capital $4.9M.
- Favorable CDI-988 Phase 1 safety/tolerability data for all doses including 1200 mg; Phase 1b norovirus challenge study planned in 2025.
- CC-42344 Phase 2a challenge study extended due to low influenza infection rates; compound active against H5N1 avian strain.
- R&D expenses $1.1M in Q2 2025 vs $4.3M in Q2 2024; G&A $1.0M vs $1.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/0001641172-25-023727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer